Pharma stocks fall after Trump announces up to 200% tariff on generic drugs
A proposed tariff of up to 200% on generic drugs would significantly disrupt pharmaceutical import flows and sourcing.
Source →The trace
How it reaches your house.
Starting from Aurobindo Pharma, we walked the supply graph hop by hop to the goods you buy and the companies you own. Each step is the engine’s reasoning, scored for confidence and cited where a source backs it.
First impact
Aurobindo Pharma →Prices riseUS generic medicine imports
The proposed tariff applies to generic imports from all countries, so it raises the landed cost of the US generic import channel that Aurobindo serves through its US-exposed portfolio.
“The proposed tariff would cover generic imports from all countries and is not directed specifically at India.”
82% confidenceCited →Sun Pharmaceutical Industries →Prices easePsychiatric Drug Active Pharmaceutical Ingredients
If Trump’s tariff hits Sun Pharma’s generics business, Sun is likely to scale back purchases of this API input; with only 10% market share and moderate substitutability, the more defensible market effect is softer demand and lower API prices rather than a supply shortage.
58% confidenceHop 2
Psychiatric Drug Active Pharmaceutical Ingredients →Prices riseAntidepressants and mental health medications
Psychiatric drug active ingredients are a critical input to these medications, so a 200% tariff that disrupts API import flows should pass through as materially higher finished-drug costs.
93% confidence
Where it lands
What you buy, and what you own.
Goods you buy
Antidepressants and mental health medications
Companies you may own
No named companies on this path.
Tap a company to see what it told the SEC could break it.
In the MyPRIA app, this is checked against your own holdings.